Related Experiment Video

Updated: May 6, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

7.4K

Targeting PCSK9 for hypercholesterolemia

Giuseppe Danilo Norata1, Gianpaolo Tibolla, Alberico Luigi Catapano

  • 1Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy; email: danilo.norata@unimi.it , gianpaolo.tibolla@unimi.it , alberico.catapano@unimi.it.

Annual Review of Pharmacology and Toxicology
|October 29, 2013
PubMed

Insights

New therapies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) show promise for managing dyslipidemia. Monoclonal antibodies inhibiting PCSK9 significantly reduce low-density lipoprotein cholesterol (LDL-C) levels, offering a potential advancement in cardiovascular disease prevention.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Genetics

Background:

  • Dyslipidemias are a major risk factor for cardiovascular disease.
  • Research has identified key genes and proteins, like PCSK9, for targeted therapy.
  • PCSK9 regulates low-density lipoprotein cholesterol (LDL-C) by affecting the LDL receptor (LDLR).

Purpose of the Study:

  • To explore novel pharmacological targets for improving lipoprotein profiles in dyslipidemia.
  • To investigate the potential of inhibiting PCSK9 activity for cardiovascular risk reduction.

Main Methods:

  • Review of biological and genetic research on dyslipidemia targets.
  • Exploration of various strategies to inhibit PCSK9 activity, including antibodies, small molecules, and gene silencing.
  • Analysis of data from ongoing Phase III studies and clinical trials.

Main Results:

  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a promising therapeutic strategy.
  • Monoclonal antibodies targeting PCSK9 have demonstrated significant LDL-C reduction (65-70%).
  • PCSK9 inhibitors show efficacy as add-on therapy to statins.

Conclusions:

  • PCSK9 inhibition represents an advanced approach for managing dyslipidemia.
  • Monoclonal antibodies targeting PCSK9 are the most promising strategy currently.
  • Further clinical trials are essential to confirm the role of PCSK9 inhibitors in clinical practice.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

7.5K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
893
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
694
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
842